US stock futures are indicating a far lower start on Wall Street after the highs of yesterday, with the Dow Jones down 103 points.
Stocks in play include Gilead Sciences Inc (NASDAQ:GILD), which saw shares add 1.86% to US$81.50 after the bell, as the key FDA, approved on Wednesday a new therapy for a type of lymphoma.
It was developed by Gilead Science Inc’s Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer.
The therapy is to be sold under the name Yescarta, to treat adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments.
Elsewhere, Verizon Communications Inc (NYSE:VZ) added nearly 2%$ in pre-market after the company reported third quarter profit and revenue, which were above Wall Street expectations.
The wireless, internet and TV firm revealed net income for the three months of U8S$3.74 billion, versus US$3.75 billion, during the same period a year ago.
Verizon Loses 18,000 Pay TV Subscribers in Third Quarter https://t.co/VskQyplWUC pic.twitter.com/9EgpMs0sL7
— Hollywood Reporter (@THR) October 19, 2017
PayPal Holdings Inc (NASDAQ:PYPL) saw shares nudge 0.88% after hours. Analysts expect the group to post quarterly earnings at US$0.43 per share on revenues of US$3.17bn after the closing bell today.
Alcoa Corp (NYSE:AA), the aluminium giant, saw shares shed 1.57% to US$47 after hours after profit came in a bit lower than expected for the aluminum company's third quarter on Wednesday, but revenue was a slight beat.